Psychedelic drug developers traded higher in the morning hours on Thursday after Eli Lilly (LLY) agreed to acquire their peer AtaiBeckley (ATAI) in a deal worth up to $3.8B to strengthen its neuroscience portfolio. AtaiBeckley (ATAI) added ~33% after the companies
Psychedelic drug developers traded higher in the morning hours on Thursday after Eli Lilly (LLY) agreed to acquire their peer AtaiBeckley (ATAI) in a deal worth up to $3.8B to strengthen its neuroscience portfolio.
AtaiBeckley (ATAI) added ~33% after the companies
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
